NCT03948100 Dyadic Yoga Intervention in Improving Physical Performance and Quality of Life in Patients With Stage I-IV Non-small Cell Lung or Esophageal Cancer Undergoing Radiotherapy and Their Caregivers
| NCT ID | NCT03948100 |
| Status | Recruiting |
| Phase | — |
| Sponsor | M.D. Anderson Cancer Center |
| Condition | Esophageal Carcinoma |
| Study Type | INTERVENTIONAL |
| Enrollment | 400 participants |
| Start Date | 2018-12-20 |
| Primary Completion | 2027-04-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 400 participants in total. It began in 2018-12-20 with a primary completion date of 2027-04-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This trial studies how well dyadic yoga intervention works in improving physical performance and quality of life in patients with stage I-IV non-small cell lung or esophageal cancer undergoing radiotherapy and their caregivers. Dyadic yoga intervention may help to improve physical function, fatigue, sleep difficulties, depressive symptoms, and overall quality of life for patients with non-small cell lung cancer and/or their caregivers.
Eligibility Criteria
Inclusion Criteria: * PATIENT ONLY: Diagnosed with stage I-IV non-small cell lung cancer (NSCLC) or esophageal cancer and going to receive at least 3 weeks of thoracic radiotherapy (RT) * PATIENT ONLY: Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2 * PATIENT ONLY: Able to read, write and speak English * PATIENT ONLY: Able to provide informed consent * PATIENT ONLY: Having a family caregiver (e.g., spouse, sibling, adult child) who assists the patient during the cancer treatment (e.g., emotional support, transportation, meal preparation, care coordination, etc) per patient self-report. Note, patients must identify a family caregiver; however, the participation of the family caregiver is optional. For caregivers to be eligible, they must be at least 18 years old; able to read, write and speak English; and able to provide informed consent. Family caregivers may consent to participate in the intervention and caregiver assessments or only the assessments based on their preference. Exclusion Criteria: * PATIENT ONLY: Who have regularly (self-defined) participated in a mind-body practice in the year prior to diagnosis * PATIENT ONLY: Patients who metastatic disease involving the central nervous system
Contact & Investigator
Kathrin Milbury
PRINCIPAL INVESTIGATOR
M.D. Anderson Cancer Center
Frequently Asked Questions
Who can join the NCT03948100 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Esophageal Carcinoma. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT03948100 currently recruiting?
Yes, NCT03948100 is actively recruiting participants. Contact the research team at kmilbury@mdanderson.org for enrollment information.
Where is the NCT03948100 trial being conducted?
This trial is being conducted at Houston, United States.
Who is sponsoring the NCT03948100 clinical trial?
NCT03948100 is sponsored by M.D. Anderson Cancer Center. The principal investigator is Kathrin Milbury at M.D. Anderson Cancer Center. The trial plans to enroll 400 participants.